GSK seeks to expand use of Benlysta drug beyond lupus
LONDON, April 3
LONDON, April 3 (Reuters) - GlaxoSmithKline is trying to expand the market for its Benlysta drug beyond lupus by launching a major study of the medicine as a treatment for a serious blood vessel disorder.
GSK acquired full control of Benlysta when it bought Human Genome Sciences for $3 billion last year. Current sales of the drug are modest, at 70 million pounds ($106 million) in 2012, but GSK hopes it will become a major seller.
Britain's biggest drugmaker said on Wednesday it was starting a final-stage Phase III clinical study to assess Benlysta in treating a particular type of vascular disease called ANCA associated vasculitis.
Vasculitis occurs when the body's immune system attacks blood vessels leading to inflammation, resulting in disruption of blood flow that can cause organ damage.
- Police hunt for motive as search for Malaysian jet spans hemispheres |
- Crimeans vote on union with Russia as troops build up rapidly |
- Malaysian PM says lost airliner was diverted deliberately |
- Democrats seek ways to limit Obamacare fallout after Florida defeat
- Indian Ocean poses daunting challenge in search for missing Malaysia plane